CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Methotrexate +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000395
NCT00000395Phase 2Completed

Mechanisms of Antifolate Efficacy in Arthritis

University of Alabama at Birmingham·interventional·Posted Nov 4, 1999·Updated Dec 16, 2016

In Brief

A Phase 2 clinical trial evaluating Methotrexate, Folinic acid, and 1 other intervention for Rheumatoid Arthritis and Adjuvant Arthritis. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This study looks at how the arthritis drug methotrexate works in low doses to treat rheumatoid arthritis. (High doses of methotrexate are used to treat some types of cancer.) Methotrexate blocks the action of the B-vitamin known as folic acid. We are studying the biochemical reactions affected by this vitamin because we think that blocking many of these reactions may be necessary for methotrexate to work in treating rheumatoid arthritis. Through these studies, we hope to gain a better understanding of how this drug and related drugs work as treatments for arthritis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
19961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedNov 4, 1999
Enrollment StartSep 1, 1996
Primary CompletionAug 1, 2002
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 26.7 years ago

Interventions

Methotrexatedrug

Folinic aciddietary

Folic aciddietary